Auxilium announced that the Food and Drug Administration (FDA) has approved a supplemental Biologics Application (sBLA) for Xiaflex (collagenase clostridium histolyticum) for the treatment of up to two Dupuytren’s contracture joints in the same hand during a single treatment visit.

The expanded approval was based on data from the MULTICORD trial, a global, multicenter Phase 3b study, along with data from the AUX-CC-861 and AUX-CC-864 studies. The MULTICORD trial also studied efficacy and safety of the finger extension procedure at 24, 48, and 72 hours post-injection. The study demonstrated that 2 injections were safely used in the treatment of one hand with multiple affected joints.

RELATED: FDA Accepts sBLA for Xiaflex for Concurrent Treatment of Multiple Palpable Cords

Also, the Xiaflex REMS will be modified to reflect a change in the contraindication section with the addition of information related to the risk of skin lacerations in the treated finger or hand of patients with Dupuytren’s contracture.


Continue Reading

Xiaflex is a biologic that is already approved for the treatment of adult Dupuytren’s contracture patients with a palpable cord, and for the treatment of adult males with Peyronie’s disease with a palpable plaque and penile curvature deformity of >30 degrees.

For more information call (877) 633-0412 or visit Xiaflex.com.